![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/25/2903646/0/en/BioXcel-Therapeutics-Announces-Positive-Topline-Results-from-Post-Marketing-Requirement-Study-Evaluating-PRN-Treatment-of-IGALMI-dexmedetomidine-Sublingual-Film-for-Agitation-Assoc.html
https://www.globenewswire.com/news-release/2024/05/28/2888870/0/en/BioXcel-Therapeutics-to-Present-at-Jefferies-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/21/2885441/0/en/BioXcel-Therapeutics-Announces-Oral-and-Poster-Presentations-at-the-2024-American-Society-of-Clinical-Psychopharmacology-ASCP-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/09/2878604/0/en/BioXcel-Therapeutics-Reports-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/04/25/2869488/0/en/BioXcel-Therapeutics-to-Report-First-Quarter-2024-Financial-Results-on-May-9-2024.html
https://www.globenewswire.com/news-release/2024/04/24/2868783/0/en/BioXcel-Therapeutics-Announces-Late-Breaking-Abstract-on-Preliminary-Findings-from-Phase-2-Investigator-Sponsored-Trial-of-BXCL701-and-KEYTRUDA-in-Metastatic-Pancreatic-Ductal-Aden.html
https://www.globenewswire.com/news-release/2024/04/22/2866727/0/en/BioXcel-Therapeutics-Announces-Plan-for-Evaluating-BXCL501-in-the-At-Home-Setting-to-Expand-Its-Market-Potential.html
https://www.globenewswire.com/news-release/2024/04/10/2860623/0/en/BioXcel-Therapeutics-Announces-TRANQUILITY-In-Care-Pivotal-Phase-3-Trial-Plan-With-BXCL501-for-Agitation-Associated-With-Alzheimer-s-Dementia.html
https://www.globenewswire.com/news-release/2024/03/25/2851487/0/en/BioXcel-Therapeutics-Announces-25-Million-Registered-Direct-Offering.html
https://www.globenewswire.com//news-release/2024/03/15/2846944/0/en/BioXcel-Therapeutics-Announces-European-Patent-Office-s-Grant-of-Patent-for-Method-of-Treating-Agitation-in-Dementia-Using-Sublingual-Dexmedetomidine.html